Research Progress on the Multifunctionality of Dipeptidyl Peptidase 4 and the Mechanism of Action of Related Drug Targets
Keywords:
Dipeptidyl peptidase 4, Drug target, Inflammatory response, Tissue repair, Energy metabolism, Chronic liver diseaseAbstract
Dipeptidyl peptidase 4 (DPP4) is a serine membrane-anchored exopeptidase that plays an important regulatory role in various physiological or pathological processes in the human body. DPP4 not only acts as a transcription factor to regulate the transcription and expression of downstream target genes, but also functions as a regulator independent of transcription, exerting its regulatory effects through protein-protein interactions. In current research, DPP4 is closely related to a variety of diseases, and multiple substances with potential targeting of DPP4 have been discovered. This article mainly reviews the multifunctionality of DPP4 in regulating various aspects such as energy metabolism, inflammation, tissue repair, and carcinogenesis. Simultaneously, based on the pathological development process of chronic liver disease, it also summarizes the screening of DPP4 inhibitors in vitro and their research progress in regulating chronic liver disease.
References
Love KM, Liu Z, 2021, DPP4 Activity, Hyperinsulinemia, and Atherosclerosis. Journal of Clinical Endocrinology Metabolism, 106(6): 1553–1565.
Li S, Wu X, Chen W, 2023, Study on the Mechanism of Erhuang Quzhi Granules in Treating Nonalcoholic Fatty Liver Disease Based on the NF-kB/NLRP3 Signaling Pathway. Chinese Pharmacological Bulletin, 39(7): 1371–1377.
Xie Y, Zhou Q, He Q, et al., 2023, Opportunities and Challenges of Incretin-Based Hypoglycemic Agents Treating Type 2 Diabetes Mellitus from the Perspective of Physiological Disposition. Acta Pharmaceutica Sinica B, 13(6): 2383–2402.
Huang CW, Lee SY, Du CX, et al., 2023, Soluble Dipeptidyl Peptidase-4 Induces Epithelial-Mesenchymal Transition Through Tumor Growth Factor-β Receptor. Pharmacology Reports, 75(4): 1005–1016.
Knerr PJ, Mowery SA, Douros JD, et al., 2022, Next Generation GLP-1/GIP/Glucagon Triple Agonists Normalize Body Weight in Obese Mice. Molecular Metabolism, 63: 101533.
Barchetta I, Cimini FA, Dule S, et al., 2022, Dipeptidyl Peptidase 4 (DPP4) as a Novel Adipokine: Role in Metabolism and Fat Homeostasis. Biomedicines, 10(9): 2306.
Wang X, Ke J, Zhu Y, et al., 2021, Dipeptidyl Peptidase-4 (DPP4) Inhibitor Sitagliptin Alleviates Liver Inflammation of Diabetic Mice by Acting as a ROS Scavenger and Inhibiting the NF-kB Pathway. Cell Death and Discovery, 7(1): 236.
Valencia I, Vallejo S, Dongil P, et al., 2022, DPP4 Promotes Human Endothelial Cell Senescence and Dysfunction via the PAR2-COX-2-TP Axis and NLRP3 Inflammasome Activation. Hypertension, 79(7): 1361–1373.
Ku HC, Chen WP, Su MJ, 2013, DPP4 Deficiency Exerts Protective Effect Against H2O2-Induced Oxidative Stress in Isolated Cardiomyocytes. PLoS One, 8(1): e54518.
Daza-Arnedo R, Rico-Fontalvo JE, Pajaro-Galvis N, et al., 2021, Dipeptidyl Peptidase-4 Inhibitors and Diabetic Kidney Disease: A Narrative Review. Kidney Medicine, 3(6): 1065–1073.
Kim M, Go J, Kwon JH, et al., 2022, CD26 Inhibition Potentiates the Therapeutic Effects of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells by Delaying Cellular Senescence. Frontiers in Cell Development Biology, 9: 803645.
Khalil R, Diab-Assaf M, Lemaitre JM, 2023, Emerging Therapeutic Approaches to Target the Dark Side of Senescent Cells: New Hopes to Treat Aging as a Disease and to Delay Age-Related Pathologies. Cells, 12(6): 915.
Hui Y, Xu Z, Li J, et al., 2023, Nonenzymatic Function of DPP4 Promotes Diabetes-Associated Cognitive Dysfunction Through IGF-2R/PKA/SP1/ERp29/IP3R2 Pathway-Mediated Impairment of Treg Function and M1 Microglia Polarization. Metabolism, 138: 155340.
He Q, Cao H, Zhao Y, et al., 2022, Dipeptidyl Peptidase-4 Stabilizes Integrin a4β1 Complex to Promote Thyroid Cancer Cell Metastasis by Activating Transforming Growth Factor-Beta Signaling Pathway. Thyroid, 32(11): 1411–1422.
Zhang G, Cui R, Kang Y, et al., 2019, Testosterone Propionate Activated the Nrf2-ARE Pathway in Ageing Rats and Ameliorated the Age-Related Changes in Liver. Science Report, 9(1): 18619.
Jang JH, Janker F, Arni S, et al., 2017, MA04.10 Lung Cancer Growth is Suppressed by CD26/DPP4-Inhibition via Enhanced NK Cell and Macrophage Recruitment. Journal of Thoracic Oncology, 12(1): S362–S363.
Kushiyama S, Yashiro M, Yamamoto Y, et al., 2022, Dipeptidyl Peptidase-4 from Cancer-Associated Fibroblasts Stimulates the Proliferation of Scirrhous-Type Gastric Cancer Cells. Anticancer Research, 42(1): 501–509.
Cui X, Yun X, Sun M, et al., 2023, HMGCL-Induced β-Hydroxybutyrate Production Attenuates Hepatocellular Carcinoma via DPP4-Mediated Ferroptosis Susceptibility. Hepatology International, 17(2): 377–392.
Ben-Shlomo S, Zvibel I, Shnell M, et al., 2011, Glucagon-Like Peptide-1 Reduces Hepatic Lipogenesis via Activation of AMP-Activated Protein Kinase. Journal of Hepatology, 54(6): 1214–1223.
Wang X, Ke J, Zhu Y, et al., 2021, Dipeptidyl Peptidase-4 (DPP4) Inhibitor Sitagliptin Alleviates Liver Inflammation of Diabetic Mice by Acting as a ROS Scavenger and Inhibiting the NF-kB Pathway. Cell Death and Discovery, 7(1): 236.
Chen L, Zhang X, Zhang L, et al., 2020, Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease. Diabetes, Metabolic Syndrome and Obesity, 13: 3507–3518.
Jin R, Ren H, Liao M, et al., 2021, A Dipeptidyl Peptidase IV Inhibitory Peptide Relieves Palmitic Acid-Induced Endoplasmic Reticulum Stress in HepG2 Cells Independent of Inhibiting Dipeptidyl Peptidase IV Activity. Food Function, 12(21): 10773–10782.
Nishina S, Yamauchi A, Kawaguchi T, et al., 2019, Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice. Cellular and Molecular Gastroenterology and Hepatology, 7(1): 115–134.
Wang K, Zhang Z, Hang J, et al., 2023, Microbial-Host-Isozyme Analyses Reveal Microbial DPP4 as a Potential Antidiabetic Target. Science, 381(6657): eadd5787.